Patients who present with hemophilia A require treatment to replace low levels of Factor VIII
(FVIII). Intervention can either be on demand or prophylactically. The goal of therapy is to …

Hemophilia has evolved from an often fatal hereditary bleeding disorder to a disorder for
which safe and effective treatment is available. However, there are several challenges …

The development of therapeutic strategies for the treatment of hemophilia A has been a long-
lasting issue since the initial identification of the disease in the early 19th century and has …

Introduction Hemophilia is a lifelong, genetic-bleeding disorder, which inadequately treated
results in permanent joint damage. It is characterized by spontaneous and trauma-related …

The last two decades has seen significant progress in the treatment of hemophilia A. The
development of highly purified and recombinant FVIII pharmaceutical products has …

The evolution of hemophilia treatment and care is a fascinating one but has been fraught
with many challenges at every turn. Over the last 50 years or so patients with hemophilia …

Hemophilia has historically been undiagnosed and untreated. Effective treatment began in
the 1960s, first with the discovery that cryoprecipitate was enriched in factor VIII, followed …

The current treatment of haemophilia relies on intravenous administration several times a
week of clotting factors VIII (FVIII) or IX (FIX) concentrates, either derived from plasma or …

Hemophilia A is an X-linked bleeding disorder that occurs in 1: 5000 live male births
worldwide and is characterized by a decrease in factor VIII (FVIII) level and elevated partial …

In the last few decades dramatic improvements in the management of haemophilia patients
have occurred. Haemophilia has moved from a fatal or disabling disease to a hereditary …